We keep you up-to-date about the happenings on the field of PH and rare diseases and provide you with healthcare-related news in the European Union and beyond.
Report on the EPF Annual General Meeting 2025
The European Patients’ Forum (EPF) is an independent, non-profit umbrella organisation representing 78 patient organisations across Europe, encompassing various disease areas and national coalitions.
Report from the 5th Baltic PH Conference, Kaunas, Lithuania
The 5th Baltic Pulmonary Hypertension (PH) Conference convened on May 9, 2025, in the historic city of Kaunas, Lithuania.
Report from the 9th ERN-LUNG Annual Board Meeting
The 9th Annual ERN-LUNG Board Meeting was held at the historic Hôpital Bicêtre in Paris. The meeting brought together representatives from all core networks, functional committees, patient organizations, and partner institutions to review current projects, share updates, and discuss future strategies.
PHAEUROPE at the European Parliament: Advocating for Better Lung Health
On February 4th and 5th, I hade the privilege to represent PHAEUROPE in two significant events at the European Parliament - the Healthy Lungs for Life exhibition and EFA’s event on raising standards of COPD care.
EUPATI Patient Expert Training Programme
In October 2023, the 7th cohort of the EUPATI Patient Expert Training Programme celebrated its graduation after a comprehensive year-long journey.
My Participation in the ERS Congress 2024
The ERS Congress 2024 in Vienna attracted close to 20,000 delegates, both onsite and online, making it a vibrant and dynamic event focused on advancing respiratory health.
ELF Networking Day at the ERS Congress
Before the official opening of the ERS Congress, I had the opportunity to participate in the ELF (European Lung Foundation) Networking Day, which set the stage for discussions on patient empowerment and the critical role of clean air in health.
Proceedings from the 7th World PH Symposium is Now Published
I am thrilled to share that the proceedings from Task Force 1 (Patient Perspective) at the 7th World Pulmonary Hypertension Symposium (WPHS) have been published in the European Respiratory Journal (ERJ).
EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).